Which one of the following is not used as a tumor marker in testicular tumours?
**Question:** Which one of the following is not used as a tumor marker in testicular tumors?
A. Alpha-fetoprotein (AFP)
B. Beta-human chorionic gonadotropin (β-hCG)
C. Lactate dehydrogenase (LDH)
D. Prostatic acid phosphatase (PAP)
**Correct Answer: D. Prostatic acid phosphatase (PAP)**
**Core Concept:** Tumor markers are substances that increase or decrease in the bloodstream in response to the presence of certain types of tumors. These markers can aid in diagnosis, monitoring treatment progress, and detecting tumor recurrence. In testicular tumors, commonly used tumor markers include AFP, β-hCG, and LDH.
**Why the Correct Answer is Right:** Prostatic acid phosphatase (PAP) is primarily associated with prostate cancer and not specific to testicular tumors. While testicular tumors can also secrete PAP, its primary use is in the context of prostate cancer diagnosis and monitoring, making it an unsuitable choice for testicular tumor marker assessment.
**Why Each Wrong Option is Incorrect:**
**A. Alpha-fetoprotein (AFP):** AFP is commonly elevated in patients with germ cell tumors of the testis, including seminomas and non-seminomas. It is considered a reliable marker for testicular cancer and is used in its diagnosis and monitoring.
**B. Beta-human chorionic gonadotropin (β-hCG):** β-hCG is elevated in patients with germ cell tumors and is particularly useful in monitoring the response to treatment and detecting recurrence of these tumors. It is a reliable marker for testicular cancer.
**C. Lactate dehydrogenase (LDH):** LDH is elevated in various cancers, including testicular tumors, as well as in other conditions like liver disease, heart failure, and muscle injury. While it can provide some information about tumor burden, LDH is not specific to testicular cancer and is not as reliable as AFP and β-hCG.
**Clinical Pearl:** In patients suspected of having testicular cancer, a panel of tumor markers including AFP, β-hCG, and LDH is used for diagnosis and monitoring treatment response. Although PAP is elevated in testicular cancer patients, its primary use is in prostate cancer diagnosis and monitoring, making it an unsuitable choice for testicular tumor marker assessment.